NASDAQ:NVTR - Nuvectra Stock Price, Forecast & News

Nuvectra trades on the NASDAQ under the ticker symbol "NVTR."

Nuvectra Corp (NASDAQ:NVTR) released its quarterly earnings data on Monday, October, 29th. The company reported ($0.87) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.86) by $0.01. The business had revenue of $14.22 million for the quarter, compared to analyst estimates of $12.38 million. Nuvectra had a negative return on equity of 58.23% and a negative net margin of 99.08%. View Nuvectra's Earnings History.

3 analysts have issued 12-month price objectives for Nuvectra's stock. Their forecasts range from $4.00 to $18.00. On average, they expect Nuvectra's stock price to reach $10.67 in the next year. This suggests a possible upside of 8,105.1% from the stock's current price. View Analyst Price Targets for Nuvectra.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvectra in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nuvectra.

News coverage about NVTR stock has been trending extremely negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Nuvectra earned a coverage optimism score of -5.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Nuvectra.

Some companies that are related to Nuvectra include Dynatronics (DYNT), PlusTherapeuticsInc . (PSTV), Encision (ECIA), CELLECT BIOTECH/S (APOP), Neurometrix (NURO), Invivo Therapeutics (NVIV), AdvanSource Biomaterials Corpration (ASNB), Cytocore (MDIT), Valeritas (VLRX), Regenicin (RGIN), Sintx Technologies (SINT), United American Healthcare (UAHC), TearLab (TEAR), Hypertension Diagnostics (HDII) and Calmare Therapeutics (CTTC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Nuvectra investors own include Allena Pharmaceuticals (ALNA), NovaBay Pharmaceuticals (NBY), Aldeyra Therapeutics (ALDX), Avinger (AVGR), Biocept (BIOC), Deciphera Pharmaceuticals (DCPH), Fate Therapeutics (FATE), Iovance Biotherapeutics (IOVA), Rigel Pharmaceuticals (RIGL) and Ampliphi Biosciences (APHB).

Shares of NVTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVTR stock can currently be purchased for approximately $0.13.

Nuvectra has a market capitalization of $2.33 million and generates $48.83 million in revenue each year. The company earns $-48,130,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Nuvectra employs 197 workers across the globe.View Additional Information About Nuvectra.

The official website for Nuvectra is http://www.nuvectramed.com/.

Nuvectra's mailing address is 5830 GRANITE PKWY SUITE 1100, PLANO TX, 75024. The company can be reached via phone at 214-474-3103 or via email at [email protected]